Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer

Large amounts of studies have proved that the development of tumor vessels mainly depend on the activation, proliferation, adhesion and maturity of vascular endothelial cells, which may also become the targets of vascular inhibitors. At present, Avastin, an anti-angiogenesis drug, has been marketed in Euopean and American countries, and another 30 kinds of vascular inhibitors are still in trails. Endostatin has been widely applied for the clinical treatment of partial primary and metastatic solid tumors. Endostatin combined with chemotherapy has achieved favorable progression in the treatment of non-small cell lung cancer (NSCLC). However, the research about the efficacy of Endostatin on breast cancer has just started. Breast cancer is a highly-differentiated solid tumor, indicating that it is also an indicator for Endostatin therapy. Additionally, after chemo- and radiotherapy, the primary nidi of patients with advanced breast cancer may also lead to rapid development of tumors in other locations. So Endostatin combined with chemotherapy can also improve the prognosis of patients with recurrent metastatic breast cancer, but there is rare any report at home and abroad. To further explore the above research, this study designed a randomized, opened and controlled clinical study to observe the clinical efficacy of EndostarTM Injection combined with GP/NP/GX/NX in the treatment of recurrent metastatic breast cancer.

• EndostarTM Injection (Drug), also known as Endostatin: 210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
• Gemcitabine (Drug), also known as GEM: 1.0 m/m2, iv 0.5h, d1, 8
• Navelbine (Drug), also known as NVB: 40 mg/d, iv, d1, 8
• Platinum (Drug), also known as DDP: 30 mg/m2, iv 3h, d1-3
• Xeloda Tablets: (Drug), also known as ECX: 2 000 mg/m2, po, d1-14

Primary outcomes

• response rate [2 years]: response rate that defined as the total ratio of study subjects with complete response, complete response unconfirmed and partial response after treatment. ORR=(CR+ CRu+ PR)cases/total cases×100%.

Secondary outcomes

• clinical benefit rate [2 years]: clinical benefit rate that defined as the total ratio of study subjects with complete response，partial response and stable disease more than 24 months after treatment.
• progression-free survival [2 years]: Progression-free survival (PFS) defined as the ratio of study subjects who had disease progression or died from the start of randomization.
• median survival time [2 years]: median survival time defined as the corresponding survival time when the cumulative survival rate is 50%.
• overall survival [2 years]: overall survival rate (OS) that defined as the ratio of study subjects who survived after randomization
• adverse responses [2 years]: adverse responses that defined as the evaluated by rates of all adverse reactions caused by Recombinant Human Endostatin and the changes of all indexes before and after treatment

Sex: Female, ages: 18 Years to 70 Years

Inclusion Criteria:

* Age: 18～70 years old;
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score: 0～1 score;
* All patients were diagnosed as recurrent metastatic breast cancer retreatment by histopathology and computed tomography (CT) examination;
* The measurable nidus≥1: Patients whose nidus diameter ≥ 20 mm by normal CT or magnetic resonance image (MRI) scanning, and ≥ 10 mm by spiral CT scanning;
* Patients whose blood routine, hepatorenal function, electrolyte and cardiac function were basically normal without dysfunction of primary organs. White blood cell count (WBC) ≥4.0×109/L, neutrophile granulocyte count ≥1.5×109/L, platelet (PLT) count ≥100×109/L, hemoglobin (HGB) ≥95 g/L, serum bilirubin (BIL) ≤1.5-fold upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2-fold upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl;
* The expected survival time >3 months;
* Patients who could understand this study status and had signed the informed consent forms.

Exclusion Criteria:

* Patients who had history of allergic responses to biological agents;
* Patients who were receiving other anti-tumor therapies;
* Patients without measureable nidus;
* Others, including one of the following conditions: patients with uncontrolled central nervous system (CNS) metastatic nidi, with dysfunction of important organs and severe cardiac diseases (congestive heart failure, uncontrollable arrhythmia, and angina pectoris, valvular heart disease, myocardial infarction and refractory hypertension that required long-term drug administration), with chronic infectious wound and with history of uncontrollable psychosis, and women in pregnant or lactation period.

• Shun-E Yang, Professor, Principal investigator, Third Affiliated Hospital of Xinjiang Medical University